international sales declined dramatically at 46.03% compared to the same period of the previous year. One of the issues was the delayed product delivery after the license was issued from China Food and Drug
granted a license from China Food and Drug Administration (CFDA) during the beginning of 2018 as the Company had to redesign and adjust product packaging according to the granted license as well as change
issued from China Food and Drug Administration (CFDA) at the beginning of 2018 as the Company had to redesign its packaging to comply with the requirements of the license and adjust its sales structures
, e.g., supermarket, food and restaurants (only for takeaway), drug stores. Online sales continued to grow remarkably by 150.0% YoY. Gross profit margin from sale of goods improved outstandingly to
baht or 6. 56 percent from the previous year, mainly due to a decrease of drug and medical supply cost since the volume of general patients and social security patients decreased. Besides, the Company
lagged (even as of the reporting date) • Do not reflect latest events Source: Dimension, Dimensions of Higher Expected Return and Strategic Beta, Dec 2013 38Source: Strategic beta: a deeper look at asset
of Corporate Practices, 2022 25 https://www.globalreporting.org/news/news-center/asean-companies-get-serious-about-climate-change/ Companies mentioned these corporate climate “Governance” dimension in
quite a longer process of licenses than expected, e.g., import license and food serial number from the Food and Drug Administration (FDA). In addition, the Company is in the process of adjusting its
outsourced production with fully completed services, from formulation development, research, marketing and label design and packaging services, including cosmetic product filings with the Food and Drug
filings with the Food and Drug Administration. Date of Incorporation October 31, 2005 Website www.pccalabs.co.th Head Office No. 59 Satriwittaya 2 Road, Ladprao Subdistrict, Ladprao District, Bangkok Branch